Sun Pharma Acquires Organon for $11.75 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy OGN?
Source: stocktwits
- Acquisition Overview: Sun Pharma's acquisition of Organon for $14 per share in an all-cash deal values the company at approximately $11.75 billion, expected to close in early 2027, providing Organon shareholders with a 24% premium and driving a 15% stock increase on Monday.
- Market Impact Analysis: This acquisition significantly expands Sun Pharma's footprint in women's health, biosimilars, and established branded medicines, with projected combined annual revenues of $12.4 billion, positioning the merged entity among the top 25 pharmaceutical companies globally.
- Product Portfolio Advantage: Organon's portfolio includes over 70 products across 140 countries, with recent developments in reproductive health and dermatology, such as Miudella and VTAMA, enhancing its market value and addressing critical health needs.
- Financial Strategy and Risks: Sun Pharma plans to fund the acquisition through available cash and bank financing, and despite Organon's recent leadership changes and policy shifts introducing uncertainties, the merger aims to create a stronger and more diversified platform.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 8.600
Low
5.00
Averages
8.50
High
12.00
Current: 8.600
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sun Pharma Acquires Organon for $11.75 Billion
- Acquisition Overview: Sun Pharma's acquisition of Organon for $14 per share in an all-cash deal values the company at approximately $11.75 billion, expected to close in early 2027, providing Organon shareholders with a 24% premium and driving a 15% stock increase on Monday.
- Market Impact Analysis: This acquisition significantly expands Sun Pharma's footprint in women's health, biosimilars, and established branded medicines, with projected combined annual revenues of $12.4 billion, positioning the merged entity among the top 25 pharmaceutical companies globally.
- Product Portfolio Advantage: Organon's portfolio includes over 70 products across 140 countries, with recent developments in reproductive health and dermatology, such as Miudella and VTAMA, enhancing its market value and addressing critical health needs.
- Financial Strategy and Risks: Sun Pharma plans to fund the acquisition through available cash and bank financing, and despite Organon's recent leadership changes and policy shifts introducing uncertainties, the merger aims to create a stronger and more diversified platform.
See More
Sun Pharmaceutical Acquires Organon for $11.75 Billion
- Acquisition Overview: Sun Pharmaceutical is set to acquire Organon for $11.75 billion in an all-cash deal, valuing each share at $14, which will elevate Sun Pharma into the top 25 global pharmaceutical companies, significantly enhancing its market position.
- Strategic Importance: This acquisition is viewed as a logical next step in strengthening Sun Pharma's global business, as Organon's product portfolio and global reach will complement Sun Pharma's existing operations, particularly in the key U.S. market.
- Growth in Innovative Medicines: Post-acquisition, Sun Pharma's innovative medicines segment is expected to increase its contribution to total sales from 20% in FY 2025 to 27%, indicating a positive impact on the company's revenue structure and furthering its development in the innovative medicines sector.
- Market Reaction: Following the acquisition announcement, Organon's shares surged nearly 31%, reflecting positive market sentiment towards the deal, although Sun Pharma's stock fell by 3.6%, yet the overall transaction is still seen as beneficial for its long-term growth.
See More
Sun Pharma to Acquire Organon for $11.75 Billion in Cash
- Significant Deal Size: Sun Pharmaceutical has agreed to acquire Organon for an enterprise value of $11.75 billion, marking one of the largest healthcare transactions of 2023, which is expected to significantly enhance the company's market position.
- Shareholder Returns: Under the agreement, Organon shareholders will receive $14 per share in cash, reflecting recognition of Organon's future potential while providing Sun Pharma with an opportunity to expand its product portfolio.
- Financial Impact: Post-acquisition, Sun Pharma's net debt to EBITDA ratio is expected to reach 2.3 times, indicating a cautious approach to financing structure to support future growth.
- Market Expansion: This acquisition will enhance Sun Pharma's capabilities in women's health and biosimilars while expanding its footprint in developed markets like the U.S. and Europe, with projected combined annual revenues of $12.4 billion.
See More
Sun Pharma to Acquire Organon for $14.00 per Share in Cash
- Transaction Overview: Sun Pharma has entered into a definitive agreement to acquire Organon for $14.00 per share in cash, valuing the deal at $11.75 billion, which will enhance Sun Pharma's competitiveness in the global pharmaceutical market.
- Financial Impact: Post-merger, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies with combined revenues of $12.4 billion, while EBITDA and cash flow are projected to nearly double, supporting its debt reduction strategy.
- Market Strategy: This acquisition will enable Sun Pharma to enter the biosimilars market, positioning it as a top-10 global player, while also strengthening its market position in women's health and creating a platform for future growth.
- Shareholder Value: The Organon Board believes this all-cash transaction offers compelling immediate value to shareholders, with the deal expected to close in early 2027, subject to regulatory approvals and shareholder voting.
See More
Sun Pharmaceutical to Acquire Organon for $11.75 Billion
- Acquisition Scale: Sun Pharmaceutical Industries is set to acquire Organon in an all-cash deal valued at approximately $11.75 billion, including debt, indicating the company's intent to expand its footprint in the global pharmaceutical market.
- Per Share Purchase Price: Under the agreement, Sun Pharma will buy all outstanding shares of Organon for $14.00 per share in cash, a price that reflects confidence in Organon's future growth potential.
- Market Positioning: This acquisition will grant Sun Pharma full ownership of Organon, which focuses on women's health, biosimilars, and established medicines, thereby enhancing its competitive edge in these critical sectors.
- Strategic Implications: Through this acquisition, Sun Pharma not only expands its product portfolio but also solidifies its position in the global pharmaceutical industry, particularly increasing its influence in the women's health segment.
See More
Sun Pharma to Acquire Organon for $14.00 per Share
- Transaction Details: Sun Pharma will acquire Organon for $14.00 per share in cash, valuing the deal at $11.75 billion, which will enhance Sun Pharma's competitive position in the global pharmaceutical market.
- Market Impact: Post-merger, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies with a combined revenue of $12.4 billion, further solidifying its leadership in women's health and biosimilars.
- Financial Outlook: Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2025, and post-acquisition, Sun Pharma's EBITDA and cash flow are projected to nearly double, supporting its debt reduction strategy.
- Strategic Synergies: This acquisition will not only integrate Organon's product portfolio and global reach but also provide Sun Pharma with an entry into the biosimilars market, expected to unlock significant revenue growth potential.
See More
Sun Pharma Acquires Organon for $11.75 Billion
- Acquisition Overview: Sun Pharma's acquisition of Organon for $14 per share in an all-cash deal values the company at approximately $11.75 billion, expected to close in early 2027, providing Organon shareholders with a 24% premium and driving a 15% stock increase on Monday.
- Market Impact Analysis: This acquisition significantly expands Sun Pharma's footprint in women's health, biosimilars, and established branded medicines, with projected combined annual revenues of $12.4 billion, positioning the merged entity among the top 25 pharmaceutical companies globally.
- Product Portfolio Advantage: Organon's portfolio includes over 70 products across 140 countries, with recent developments in reproductive health and dermatology, such as Miudella and VTAMA, enhancing its market value and addressing critical health needs.
- Financial Strategy and Risks: Sun Pharma plans to fund the acquisition through available cash and bank financing, and despite Organon's recent leadership changes and policy shifts introducing uncertainties, the merger aims to create a stronger and more diversified platform.
See More
Sun Pharmaceutical Acquires Organon for $11.75 Billion
- Acquisition Overview: Sun Pharmaceutical is set to acquire Organon for $11.75 billion in an all-cash deal, valuing each share at $14, which will elevate Sun Pharma into the top 25 global pharmaceutical companies, significantly enhancing its market position.
- Strategic Importance: This acquisition is viewed as a logical next step in strengthening Sun Pharma's global business, as Organon's product portfolio and global reach will complement Sun Pharma's existing operations, particularly in the key U.S. market.
- Growth in Innovative Medicines: Post-acquisition, Sun Pharma's innovative medicines segment is expected to increase its contribution to total sales from 20% in FY 2025 to 27%, indicating a positive impact on the company's revenue structure and furthering its development in the innovative medicines sector.
- Market Reaction: Following the acquisition announcement, Organon's shares surged nearly 31%, reflecting positive market sentiment towards the deal, although Sun Pharma's stock fell by 3.6%, yet the overall transaction is still seen as beneficial for its long-term growth.
See More
Sun Pharma to Acquire Organon for $11.75 Billion in Cash
- Significant Deal Size: Sun Pharmaceutical has agreed to acquire Organon for an enterprise value of $11.75 billion, marking one of the largest healthcare transactions of 2023, which is expected to significantly enhance the company's market position.
- Shareholder Returns: Under the agreement, Organon shareholders will receive $14 per share in cash, reflecting recognition of Organon's future potential while providing Sun Pharma with an opportunity to expand its product portfolio.
- Financial Impact: Post-acquisition, Sun Pharma's net debt to EBITDA ratio is expected to reach 2.3 times, indicating a cautious approach to financing structure to support future growth.
- Market Expansion: This acquisition will enhance Sun Pharma's capabilities in women's health and biosimilars while expanding its footprint in developed markets like the U.S. and Europe, with projected combined annual revenues of $12.4 billion.
See More
Sun Pharma to Acquire Organon for $14.00 per Share in Cash
- Transaction Overview: Sun Pharma has entered into a definitive agreement to acquire Organon for $14.00 per share in cash, valuing the deal at $11.75 billion, which will enhance Sun Pharma's competitiveness in the global pharmaceutical market.
- Financial Impact: Post-merger, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies with combined revenues of $12.4 billion, while EBITDA and cash flow are projected to nearly double, supporting its debt reduction strategy.
- Market Strategy: This acquisition will enable Sun Pharma to enter the biosimilars market, positioning it as a top-10 global player, while also strengthening its market position in women's health and creating a platform for future growth.
- Shareholder Value: The Organon Board believes this all-cash transaction offers compelling immediate value to shareholders, with the deal expected to close in early 2027, subject to regulatory approvals and shareholder voting.
See More
Sun Pharmaceutical to Acquire Organon for $11.75 Billion
- Acquisition Scale: Sun Pharmaceutical Industries is set to acquire Organon in an all-cash deal valued at approximately $11.75 billion, including debt, indicating the company's intent to expand its footprint in the global pharmaceutical market.
- Per Share Purchase Price: Under the agreement, Sun Pharma will buy all outstanding shares of Organon for $14.00 per share in cash, a price that reflects confidence in Organon's future growth potential.
- Market Positioning: This acquisition will grant Sun Pharma full ownership of Organon, which focuses on women's health, biosimilars, and established medicines, thereby enhancing its competitive edge in these critical sectors.
- Strategic Implications: Through this acquisition, Sun Pharma not only expands its product portfolio but also solidifies its position in the global pharmaceutical industry, particularly increasing its influence in the women's health segment.
See More
Sun Pharma to Acquire Organon for $14.00 per Share
- Transaction Details: Sun Pharma will acquire Organon for $14.00 per share in cash, valuing the deal at $11.75 billion, which will enhance Sun Pharma's competitive position in the global pharmaceutical market.
- Market Impact: Post-merger, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies with a combined revenue of $12.4 billion, further solidifying its leadership in women's health and biosimilars.
- Financial Outlook: Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2025, and post-acquisition, Sun Pharma's EBITDA and cash flow are projected to nearly double, supporting its debt reduction strategy.
- Strategic Synergies: This acquisition will not only integrate Organon's product portfolio and global reach but also provide Sun Pharma with an entry into the biosimilars market, expected to unlock significant revenue growth potential.
See More
